Expanding sales of Imperial Brands’ next generation products into new markets has more than compensated the company for the effect of the US Food and Drug Administration (FDA)’s marketing denial order (MDO) for its Myblu vaping product.

The company said new markets for vapour, heated tobacco and modern oral products which it groups together as its next generation product (NGP) segment brought in more than enough new revenue to offset the loss of Myblu from the US market.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us